Cancer Research

Breast cancer-killing RIG

A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.

Study examines new breast cancer drug combination

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.

V Foundation grants bolster cancer initiatives

Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC.

In search of new cancer targets

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.

New breast cancer driver

Vanderbilt investigators have demonstrated that a certain protein complex drives tumor progression in aggressive breast cancers.

Switching breast cancer off

Signaling by a receptor that is overexpressed in aggressive forms of breast cancer has been linked to glutamine metabolism, suggesting new anti-cancer therapeutic targets.

1 2 3